INV vs ACIC vs HCI vs XOMA vs UPC

For growth investors, XOMA Royalty Corp.

(XOMA) is the stronger pick with 83. 1% revenue growth year-over-year, versus -22. 4% for Universe Pharmaceuticals Inc. (UPC). American Coastal Insurance Corporation (ACIC) offers the better valuation at 4. 9x trailing P/E (7. 5x forward), making it the more compelling value choice. Analysts rate HCI Group, Inc. (HCI) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, American Coastal Insurance Corporation (ACIC) is the cheapest at 4.

9x versus XOMA Royalty Corp. at 28. 7x. On forward P/E, American Coastal Insurance Corporation is actually cheaper at 7. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: HCI Group, Inc. wins at 0. 19x versus XOMA Royalty Corp. 's 3. 99x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, HCI Group, Inc.

(HCI) delivered a total return of +114. 1%, compared to -100. 0% for Universe Pharmaceuticals Inc. (UPC). Over 10 years, the gap is even starker: HCI returned +434. 8% versus UPC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), American Coastal Insurance Corporation (ACIC) is the lower-risk stock at 0.

24β versus Innventure, Inc. 's 2. 81β — meaning INV is approximately 1087% more volatile than ACIC relative to the S&P 500. On balance sheet safety, Innventure, Inc. (INV) carries a lower debt/equity ratio of 4% versus 157% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), XOMA Royalty Corp.

(XOMA) is pulling ahead at 83. 1% versus -22. 4% for Universe Pharmaceuticals Inc. (UPC). On earnings-per-share growth, the picture is similar: XOMA Royalty Corp. grew EPS 188. 5% year-over-year, compared to -143. 1% for Innventure, Inc.. Over a 3-year CAGR, XOMA leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XOMA Royalty Corp.

(XOMA) is the more profitable company, earning 60. 8% net margin versus -64. 1% for Innventure, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCI leads at 47. 7% versus -63. 2% for INV. At the gross margin level — before operating expenses — XOMA leads at 94. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, HCI Group, Inc. (HCI) is the more undervalued stock at a PEG of 0. 19x versus XOMA Royalty Corp. 's 3. 99x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, American Coastal Insurance Corporation (ACIC) trades at 7. 5x forward P/E versus 53. 3x for XOMA Royalty Corp. — 45. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XOMA: 28. 3% to $53. 75.

In this comparison, HCI (1.

0% yield), XOMA (0. 7% yield), INV (0. 2% yield) pay a dividend. ACIC, UPC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, HCI Group, Inc.

(HCI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 38), 1. 0% yield, +434. 8% 10Y return). Innventure, Inc. (INV) carries a higher beta of 2. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCI: +434. 8%, INV: -30. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (INV (Financial Services) and ACIC (Financial Services) and HCI (Financial Services) and XOMA (Healthcare) and UPC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: INV is a small-cap quality compounder stock; ACIC is a small-cap deep-value stock; HCI is a small-cap high-growth stock; XOMA is a small-cap high-growth stock; UPC is a small-cap quality compounder stock. HCI, XOMA pay a dividend while INV, ACIC, UPC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.